Peter A. Merkel

1.8k total citations · 1 hit paper
9 papers, 567 citations indexed

About

Peter A. Merkel is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Genetics. According to data from OpenAlex, Peter A. Merkel has authored 9 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Rheumatology and 4 papers in Genetics. Recurrent topics in Peter A. Merkel's work include Vasculitis and related conditions (7 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers) and Otitis Media and Relapsing Polychondritis (4 papers). Peter A. Merkel is often cited by papers focused on Vasculitis and related conditions (7 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers) and Otitis Media and Relapsing Polychondritis (4 papers). Peter A. Merkel collaborates with scholars based in United States, United Kingdom and Canada. Peter A. Merkel's co-authors include David Jayne, Pirow Bekker, Thomas J. Schall, Emily Y. Chu, William D. James, Katrina Abuabara, Sara Samimi, Wladimir Szpirt, Mats Junek and Carmel M. Hawley and has published in prestigious journals such as New England Journal of Medicine, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Peter A. Merkel

8 papers receiving 561 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avacopan for the Treatment of ANCA-Associated Vasculitis

2021 548 citations David Jayne, Peter A. Merkel et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Peter A. Merkel

Since Specialization

Citations

This map shows the geographic impact of Peter A. Merkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. Merkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. Merkel more than expected).

Fields of papers citing papers by Peter A. Merkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter A. Merkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. Merkel. The network helps show where Peter A. Merkel may publish in the future.

Co-authorship network of co-authors of Peter A. Merkel

This figure shows the co-authorship network connecting the top 25 collaborators of Peter A. Merkel. A scholar is included among the top collaborators of Peter A. Merkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter A. Merkel. Peter A. Merkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis 2025 ·Nature Reviews Rheumatology ·Marta Casal Moura, Peter A. Merkel, David Jayne, María C. Cid, Neil Basu, Bernhard Hellmich, Benjamin Terrier, Abraham Rutgers, Jennifer Gordon, (unknown), Joyce Kullman, Carol A. Langford, Ingeborg M. Bajema, Duvuru Geetha, Fernando C. Fervenza, A. Richard Kitching, John H. Stone, Ulrich Specks, Andreas Kronbichler	0
2	Advances in the treatment of ANCA-associated vasculitis 2025 ·Nature Reviews Rheumatology ·Giorgio Trivioli, Marta Casal Moura, Andreas Kronbichler, Rona Smith, Benjamin Terrier, Stephen P. McAdoo, Rachel Jones, Peter A. Merkel, David Jayne	2
3	WCN25-1022 LONG-TERM KIDNEY FUNCTION BEYOND 12 MONTHS AND KIDNEY RELAPSE AFTER INITIATION OF TREATMENT FOR ANCA-ASSOCIATED VASCULITIS 2025 ·Kidney International Reports ·(unknown), Vanja Ivković, (unknown), Duvuru Geetha, Balazs Odler, Carmel M. Hawley, Zachary S. Wallace, Carol A. McAlear, Mats Junek, Peter A. Merkel, Michael Walsh, David Jayne, Andreas Kronbichler	1
4	Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 2025 ·Annals of the Rheumatic Diseases ·Peter A. Merkel, Parameswaran Nair, Nader Khalidi, Benjamin Terrier, Bernhard Hellmich, Arnaud Bourdin, David Jayne, David J. Jackson, Florence Roufosse, Christian Pagnoux, Ulrich Specks, (unknown), (unknown), Maria Jison, Christopher McCrae, Sofia Necander, Eva Rodríguez‐Suárez, Anat Shavit, (unknown), (unknown)	2
5	The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial 2024 ·Kidney International ·Balazs Odler, Regina Riedl, Duvuru Geetha, Wladimir Szpirt, Carmel M. Hawley, (unknown), Zachary S. Wallace, Giles Walters, (unknown), Vladimı́r Tesař, Charles D. Pusey, Mark A. Little, Peter A. Merkel, Michael Walsh, David Jayne, Andreas Kronbichler, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
6	General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis 2024 ·Journal of the American Society of Nephrology ·Duvuru Geetha, Rula A. Hajj‐Ali, Raashid Luqmani, Christian Pagnoux, (unknown), David Jayne, Peter A. Merkel	2
7	Avacopan for the Treatment of ANCA-Associated Vasculitis breakdown → 2021 ·New England Journal of Medicine ·David Jayne, Peter A. Merkel, Thomas J. Schall, Pirow Bekker	548
8	Alcohol-induced vasculitis: Case report and commentary 2014 ·Journal of the American Academy of Dermatology ·Katrina Abuabara, Sara Samimi, Emily Y. Chu, (unknown), William D. James, Peter A. Merkel	3
9	Skin ulcers in a patient with Sjögren's syndrome 2010 ·Arthritis Care & Research ·(unknown), Peter A. Merkel	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact